Perspective Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.5%projected annual EPS growth
Analyst Coverage
14analysts covering
FY EPS (est.)
-$1.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
| Q4 / Full Year 2026 Earnings Release | 16 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, cash equivalents, and short-term investments Quarterly271MTarget: Sufficient to fund clinical milestones and operational investments into late 2027
VMT-α-NET Cohort 2 Patient Follow-up Quarterly23.0Target: all 46 patients in Cohort 2 will have had the opportunity for at least 60 weeks of follow-up since beginning treatment by late 2026
Quarterly Net Loss Quarterly-26.2MTarget: Disciplined spending within planned clinical development budget
Watch Items
- VMT-α-NET Clinical Trial Progress and Regulatory EngagementTrigger: Regulatory feedback on registration-enabling study design in 2026Action: Align with FDA on the path forward for the lead program
- Chicago Manufacturing Site ConstructionTrigger: Completion of construction in 2026Action: Initiate validation and operational readiness to support clinical and commercial supply
- VMT01 and PSV359 Clinical CatalystsTrigger: Dose-escalation and safety/efficacy readouts in late 2026Action: Evaluate monotherapy and combination cohorts to determine next-phase trial designs
Research as of 20 Jun 2026